Therapeutically, enhancement in BAFF binding and its associated structural modifications shifted the treatment paradigm of sBCMA-Fc from a treatment selective for MM to a therapeutic candidate suited for targeting multiple B cell–driven diseases. Here, TNFSF13B is linked to Miyoshi myopathy.